CAJ | 학술논문

目的：探讨痰热清联合α-2b干扰素治疗小儿手足口病（HFMD）的疗效。方法将60例HFMD患儿按随机数字表法分为观察组和对照组，每组30例。2组均给予对症支持治疗，包括辅以VitC、VitB6以及补充电解质等，观察组同时给予痰热清注射液0.3～0.5 mL·kg-1·d-1，加入5%葡萄糖注射液100～250 mL中静脉滴注，1次·d-1；重组人干扰素α-2b注射液3～10万U·kg-1·d-1，皮下注射或肌内注射；对照组给予利巴韦林注射液10～15 mg·kg-1·d-1，加入5%葡萄糖注射液100～250 mL中静脉滴注，1次·d-1。2组均3 d为1个疗程。对2组患儿的临床疗效及不良反应进行比较。结果疗程结束后，观察组患者总有效率为100.00%，对照组总有效率为86.67%，2组比较差异有统计学意义(P＜0.05)。观察组患儿退热、退疹、进食、溃疡愈合及住院时间均明显短于对照组(均P＜0.05)。2组均未发生肝肾功能损害及其他严重不良反应。结论痰热清联合α-2b干扰素治疗小儿HFMD能明显提高临床治疗效果，且安全、可靠。
목적：탐토담열청연합α-2b간우소치료소인수족구병（HFMD）적료효。방법장60례HFMD환인안수궤수자표법분위관찰조화대조조，매조30례。2조균급여대증지지치료，포괄보이VitC、VitB6이급보충전해질등，관찰조동시급여담열청주사액0.3～0.5 mL·kg-1·d-1，가입5%포도당주사액100～250 mL중정맥적주，1차·d-1；중조인간우소α-2b주사액3～10만U·kg-1·d-1，피하주사혹기내주사；대조조급여리파위림주사액10～15 mg·kg-1·d-1，가입5%포도당주사액100～250 mL중정맥적주，1차·d-1。2조균3 d위1개료정。대2조환인적림상료효급불량반응진행비교。결과료정결속후，관찰조환자총유효솔위100.00%，대조조총유효솔위86.67%，2조비교차이유통계학의의(P＜0.05)。관찰조환인퇴열、퇴진、진식、궤양유합급주원시간균명현단우대조조(균P＜0.05)。2조균미발생간신공능손해급기타엄중불량반응。결론담열청연합α-2b간우소치료소인HFMD능명현제고림상치료효과，차안전、가고。
Objective To investigate the curative efficacy of Tanreqing combined with α-2b inte-rferon in children with hand, foot and mouth disease (HFMD). Methods Sixty children with HFMD were randomly divided into two groups, with 30 children in each group. All children received symptomatic and supportive treatment supplemented with vitamin C, vitamin B6 and electrolytes. In addition, children in observation group were given intravenous infusion of 5% glucose injection (100-250 mL) containing Tanreqing injection (0.3-0.5 mL·kg-1) and subcutaneous or intramuscular injection of recombinant human α-2b interferon (30 000-100 000 U·kg-1) once daily. However, children in control group were given intravenous infusion of 5% glucose injection(100-250 mL) containing ribavirin injection (10-15 mg·kg-1) once daily. Each course was repeated every 3 days. Clinical efficacies and adverse reactions were compared between the two groups. Results Compared with control group, the overall response rate was significantly increased (100.00% vs 86.67%,P<0.05), and time to fever abatement, rash clearance, eating and ulcer healing and length of hospital stay were obviously decreased in observation group (P<0.05). No liver and kidney dysfunction and other serious adverse reactions were found in both groups. Conclusion Tanreqing combined with α-2b interferon can safely and reliably improve the curative efficacy in children with HFMD.